CohBar to Present at the 3rd Annual Longevity Therapeutics Conference

On January 20, 2021 CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, reported that its Chief Executive Officer, Steven Engle, will present a company overview at the 3rd Annual Longevity Therapeutics Conference, being held virtually on January 26 – 28, 2021 (Press release, CohBar, JAN 20, 2021, View Source [SID1234574144]). This presentation will be available for registered attendees at 12:15PM PT on Thursday, January 28, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

EDAP Announces Record Preliminary Unaudited Fourth Quarter 2020 Revenue of EUR 15.3 Million [$18.3 million], an Increase of 28% Year-Over-Year

On January 20, 2021 EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in robotic energy-based therapies, reported that preliminary unaudited fourth quarter and full-year revenue for the three and twelve months ended December 31, 2020 (Press release, EDAP TMS, JAN 20, 2021, View Source [SID1234574143]). For the fourth quarter 2020, the Company anticipates record revenue of EUR 15.3 million [$18.3 million], as compared to EUR 12.0 million [$13.3 million] for the fourth quarter of 2019, an increase of 28%. For the full-year 2020, unaudited revenue is anticipated to be EUR 41.6 million [$47.8 million], as compared to EUR 44.9 million [$50.2 million] for the full-year 2019, a decrease of 7%, driven entirely by COVID-19-related restrictions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Marc Oczachowski, EDAP’s Chairman and Chief Executive Officer, said: "We are very pleased with this very strong and successful fourth quarter during which we generated record revenue that increased 28% over the prior year period. Of note, HIFU revenue increased 50% over the fourth quarter of 2019, which is all the more impressive in light of the impact the pandemic continues to have on healthcare systems around the world. This reflects the continued interest in HIFU technology and confirms that we have successfully adjusted to this new reality by continuing to grow our sales pipeline. We entered 2021 with renewed momentum, and I look forward to an exciting year."

Note: exchange rates used in the conversion of EUR to USD are: Q4 2020=1.194 and full year 2020=1.147.

Lytix Biopharma announces FDA clearance of IND for starting a Phase II study in the US

On January 20, 2021 Lytix Biopharma AS reported that it has received FDA clearance to initiate a Phase II clinical trial in the US designed to assess the efficacy of its lead candidate LTX-315, a first-in-class oncolytic peptide, in several solid tumor types (Press release, Lytix Biopharma, JAN 20, 2021, View Source [SID1234574142]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lytix Biopharma, a Norwegian clinical-stage immunoncology therapeutic company developing oncolytic molecule therapies to treat cancer, reported that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for LTX-315, an oncolytic molecule in development for various solid tumors.

"This is a significant milestone for Lytix Biopharma, as it clears a path for further clinical development towards market approval in the US, the world’s biggest and most important market for cancer treatment. This approval strengthens the belief in, and roadmap for, our drug candidate to be essential in cancer treatment in the future", said Dr. Øystein Rekdal, Lytix’s CEO.

The US market for cancer treatment in 2020 was valued at USD 70 billion, with immune therapy accounting for ~30 percent of the market, and with a 12 percent compounded annual growth rate according to Fortune Business Insights. Lytix Biopharma develops the drug candidate LTX-315 for several types of cancer.

In August 2020, Lytix entered into an exclusive worldwide license agreement with Verrica Pharmaceuticals to develop and commercialize LTX-315 for dermatologic oncology indications (skin cancer diseases). Lytix`s IND approval is for other cancer indications, but it triggers a significant milestone payment to Lytix according to the licensing agreement.

The IND approval enables Lytix to conduct a Phase II clinical trial in the US designed to assess the efficacy of LTX-315 in several types of solid tumors including metastatic breast cancer and head and neck squamous cell carcinoma. The trial will be a multicenter study including M.D. Anderson Cancer Center in Texas, which is one of the world leading cancer hospitals. In the planned Phase II study LTX-315 will be evaluated in combination with the immune checkpoint inhibitor pembrolizumab, which blocks tumor cells’ ability to inhibit the body`s immune response. Results from initial studies indicate that the combination of LTX-315 and pembroluzimab work better than pembroluzimab alone.

"The FDA clearance also confirms acceptable clinical safety-benefit ratio and manufacturing quality of LTX-315, which is an acknowledgement of the quality of work done so far in the program", said Mr. Øystein Rekdal.

One of the main challenges in current cancer therapy is tumor heterogeneity. With its unique ability to evoke the patient’s own immune system to identify and kill cancer cells with different characteristics, LTX-315 has received international attention and recognition for its potential to target tumor heterogeneity.

"A solution to heterogeneity is a key success for future cancer treatment. We believe that our candidate stands out as a promising therapeutic tool to target tumor heterogeneity and we are happy to receive international support and attention from both the scientific community and the market", Rekdal said.

In 2019, Nobel Prize Winner Jim Allison together with his wife Padmanee Sharma joined Lytix Biopharma’s advisory board. Allison received the Nobel Prize in Physiology or Medicine in 2018 for launching an effective new way to attack cancer by treating the immune system rather than the tumor.

Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference: on 21 January 2021 at 3 pm ET/8 pm GMT

On January 20, 2021 Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, reported its CEO and CSO, Dr. Kunwar Shailubhai, will participate in a fireside chat via a video link on Thursday 21 January 2021 at 3 pm ET / 8 pm GMT to provide updates on the Company (Press release, Tiziana Life Sciences, JAN 20, 2021, View Source [SID1234574140]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Thursday 21 January 2021
Time: 3 pm U.S. Eastern / 8 pm GMT
Webcast: https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup

Invitae Announces Proposed Public Offering of Common Stock

On January 20, 2021 Invitae Corporation (NYSE: NVTA) reported that it has commenced an underwritten public offering of $400.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses (Press release, Invitae, JAN 20, 2021, View Source [SID1234574139]). All of the shares are being offered by Invitae. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $60.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Invitae’s (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)

Invitae currently intends to use the net proceeds from this offering for working capital and other general corporate purposes, including investing in its platform, oncology and reproductive product extensions and international expansion. Invitae may also use a portion of the net proceeds from this offering to acquire or invest in complementary businesses, assets or technologies, although it has no present commitments or agreements to do so.

J.P. Morgan Securities LLC, Morgan Stanley, Cowen and Company, LLC and SVB Leerink LLC are acting as the book-running managers for the proposed offering.

An automatic shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and became effective on March 4, 2019. A copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at [email protected]; from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY, 10014, Attention: Prospectus Department; from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by email at [email protected], or by telephone at (833) 297-2926; or from SVB Leerink LLC, One Federal Street, 37th Floor, Boston, MA 02110, Attention: Syndicate Department, by telephone at (800) 808-7535, ext. 6132, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.